

KEY MESOBLAST PATENT CLAIMS UPHELD IN EUROPE

New York, USA; and Melbourne, Australia; 16 December 2014 – Mesoblast Limited (ASX:MSB; USOTC:MBLTY) reported today that the European Patent Office (EPO) upheld key claims in Mesoblast’s European patent (EP 1 727 892 B1) covering the use of Mesenchymal Stem Cells (MSCs) for inflammatory bowel diseases, multiple sclerosis, and autoimmune encephalomyelitis.

The EPO Opposition Division based in Munich, Germany, rejected all grounds of the opposition mounted by a third party opponent. Mesoblast’s patent claims were found to be valid in their originally granted form.

The opposition related to Mesoblast’s European patent number EP 1 727 892 B1 based on application number EP 05 725 577.0. Opponents challenged the patent as a whole and supported its arguments and notice of opposition with 29 documents. The EPO Opposition Division upheld the patent without amendment against all allegations of Added Matter (Article 100(c)/Article 123(2) EPC), lack of Priority (Article 87 EPC), lack of Novelty (Article 100(a)/Article 54 EPC), lack of Inventive Step (Article 100(a)/Article 56 EPC) and Insufficient Disclosure (Article 100(b)/Article 83 EPC).

Mesoblast Chief Executive Silviu Itescu said: “We will vigorously defend our robust intellectual property estate and commercial rights, and are pleased that our patent position in the use of MSCs for inflammatory bowel diseases and demyelinating nerve diseases has been validated. Management of our intellectual property, which comprises more than 60 patent families, has high priority as part of our ongoing efforts to maintain and augment the value of our advanced pipeline of novel cell-based product candidates.”

Mesoblast Limited

Mesoblast Limited (ASX: MSB; USOTC: MBLTY) is a global leader in regenerative medicine. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells (MLCs), to establish a broad portfolio of late stage product candidates. Mesoblast’s allogeneic or ‘off-the-shelf’ cell product candidates target significantly advanced stages of diseases where there are highly unmet medical needs, including orthopedic disorders, cardiovascular disorders, immunologic/inflammatory disorders and oncology / hematology conditions. Lead product candidates under investigation include MPC-06-ID for chronic discogenic low back pain, MPC-150-IM for chronic congestive heart failure, in partnership with Teva Pharmaceutical Industries Ltd., and MSC-100-IV for acute graft versus host disease (aGVHD).

For further information, please contact:

Julie Meldrum
Global Head of Corporate Communications
Mesoblast Limited
T: +61 (0) 3 9639 6036
E: julie.meldrum@mesoblast.com

Mesoblast Limited
ABN 68 109 431 870
www.mesoblast.com

Corporate Headquarters
Level 38
55 Collins Street
Melbourne 3000
Victoria Australia
T +61 3 9639 6036
F +61 3 9639 6030

United States Operations
505 Fifth Avenue
Third Floor
New York, NY 10017
USA
T +1 212 880 2060
F +1 212 880 2061

Asia
20 Biopolis Way
#05-01 Centros
Biopreneur 3
SINGAPORE 138668
T +65 6570 0635
F +65 6570 0176